Rafaela Pires da Silva

Ms. Rafaela Pires da Silva

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RSRafaela Pires da Silva
Rafaela Pires da Silva
JGJoão Ismael Budelon Gonçalves
João Ismael Budelon Gonçalves
RZRafael Fernandes Zanin
Rafael Fernandes Zanin
FSFelipe Barreto Schuch
Felipe Barreto Schuch
ASAna Paula Duarte De Souza
Ana Paula Duarte De Souza
Introduction: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, resulting in a range of clinical manifestations and outcomes. Laboratory and immunological alterations have been considered as potential markers of disease severity and clinical evolution. Type I interferons (IFN-I), mainly represented by IFN-α and β, are a group of cytokines with an important function in antiviral responses and have played a complex role in COVID-19. Some studies have demonstrated that IFN-I levels and interferon response is elevated in mild cases, while other studies have noted this in severe cases. The involvement of IFN-I on the pathogenesis and outcomes of SARS-CoV-2 infection remains unclear. In this study, we summarize the available evidence of the association of plasma protein levels of type I IFN with the severity of COVID-19. Methods: The PRISMA checklist guided the reporting of the data. A systematic search of the MEDLINE (PubMed), EMBASE, and Web of Science databases was performed up to March of 2021, looking for articles that evaluated plasma protein levels of IFN-I in mild, severe, or critical COVID-19 patients. Comparative meta-analyses with random effects were performed to compare the standardized mean differences in plasma protein levels of IFN-I of mild versus severe and mild versus critical patients. Meta-regressions were performed to test the moderating role of age, sex, time that the IFN-I was measured, and limit of detection of the assay used in the difference between the means. Results: There was no significant difference in plasma levels of IFN-α when comparing between mild and severe patients (SMD = -0.236, 95% CI -0.645 to 0.173, p = 0.258, I2 = 82.11), nor when comparing between patients mild and critical (SMD = 0.203, 95% CI -0.363 to 0.770, p = 0.481, I2 = 64.06). However, there was a significant difference between healthy individuals and patients with mild disease (SMD = 0.447, 95% CI 0.085 to 0.810, p = 0.016, I2 = 62.89). Conclusions: Peripheral IFN-α cannot be used as a severity marker as it does not determine the clinical status presented by COVID-19 patients.

9 September 2023 in Biology
Verified
Journal Article
Open access
PDF file
RSRafaela Pires da Silva
Rafaela Pires da Silva
BTBibiana Thomé
Bibiana Thomé
ASAna Paula Duarte De Souza
Ana Paula Duarte De Souza
Viral respiratory tract infections are a significant public health concern, particularly in children. RSV is a prominent cause of lower respiratory tract infections among infants, whereas SARS-CoV-2 has caused a global pandemic with lower overall severity in children than in adults. In this review, we aimed to compare the innate and adaptive immune responses induced by RSV and SARS-CoV-2 to better understand differences in the pathogenesis of infection. Some studies have demonstrated that children present a more robust immune response against SARS-CoV-2 than adults; however, this response is dissimilar to that of RSV. Each virus has a distinctive mechanism to escape the immune response. Understanding the mechanisms underlying these differences is crucial for developing effective treatments and improving the management of pediatric respiratory infections.

16 June 2025 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
MAMarina Chaves Amantéa
Marina Chaves Amantéa
RSRafaela Pires da Silva
Rafaela Pires da Silva
LSLarissa Ranini Soares
Larissa Ranini Soares
JPJoão Lorenzo de Medeiros Pereira
João Lorenzo de Medeiros Pereira
ASAna Paula Duarte De Souza
Ana Paula Duarte De Souza
CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.